AK-OTOF at COSM 2026: 8 of 10 children on the higher dose gained hearing, with no therapy-related adverse events

Eli Lilly/AK-OTOF (Akouos)

Updated AK-OTOF-101 results covered 18 participants across two dose levels, including early two-ear treatments. At the higher dose, 80% improved to at least a moderate level of hearing loss, with brainstem responses from about 30 days. A long-term study will follow patients about 4 more years and track speech and language.

• 8 of 10 higher-dose children improved on the four-frequency average hearing test.
• Earliest participants have been followed for up to 2 years.
• No serious adverse events related to the gene therapy, the device or the procedure.
• Delivered with a single-use device needing no skin incisions or bone drilling.